Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma

References

• Liver-fact-sheet. International agency for research on cancer. GLOBOCA, IARC; 2020.
   Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut. 2023;72(1):141–152. doi:10.1136/gutjnl-2021-324915
   PubMed Web of Science ®Google Scholar
• Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–530. doi:10.1016/S1470-2045(22)00078-X
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2019;38:193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Fulgenzi CA, Scheiner B, Korolewicz J, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials. JHEP Reports. 2023;5:100702. doi:10.1016/j.jhepr.2023.100702
   PubMedGoogle Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncology. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39(18):3620–3637. doi:10.1038/s41388-020-1249-9
   PubMed Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi:10.1016/S1470-2045(22)00326-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Merle P, et al. LBA34 - Primary results from the phase III LEAP-002 study: lenvatinib+pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Anna Oncol. 2022;2022:S808–S869.
   Google Scholar
• Yau T, Zagonel V, Santoro A, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the checkMate 040 trial. J Clin Oncol. 2022;41:1747–1757. doi:10.1200/JCO.22.00972
   PubMedGoogle Scholar
• Merle P, Blanc JF, Edeline J, et al. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Digest Liver Dis. 2023;55(4):464–470. doi:10.1016/j.dld.2023.01.161
   Web of Science ®Google Scholar
• Cabibbo G, Enea M, Attanasio M, Bruix J, Craxí A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274–1283. doi:10.1002/hep.23485
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-4
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SMB, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–7392. doi:10.1158/0008-5472.CAN-09-1089
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. doi:10.1053/j.gastro.2017.06.007
   PubMed Web of Science ®Google Scholar
• Montironi C, Castet F, Haber PK, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut. 2022;72:129–140. doi:10.1136/gutjnl-2021-325918
   PubMed Web of Science ®Google Scholar
• Gao X, Huang H, Wang Y, et al. Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four prognostic and immunotherapeutically relevant subclasses. Front Oncol. 2021;10:610513. doi:10.3389/fonc.2020.610513
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456. doi:10.1038/s41586-021-03362-0
   PubMed Web of Science ®Google Scholar
• Fulgenzi CAM, Cheon J, D’Alessio A, et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study. Eur J Cancer. 2022;175:204–213. doi:10.1016/j.ejca.2022.08.024
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147–164. doi:10.1200/EDBK_240837
   PubMedGoogle Scholar
• Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities. Front Oncol. 2022;2022:12.
   Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1). doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol. 2015;7(17):2080–2090. doi:10.4254/wjh.v7.i17.2080
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England J Med. 2016;375(9):819–829. doi:10.1056/NEJMoa1604958
   PubMed Web of Science ®Google Scholar
• Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420–1435. doi:10.1158/2159-8290.CD-17-0593
   PubMed Web of Science ®Google Scholar
• De A, Coste LA, Romagnolo B, et al. Somatic mutations of the-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proceed Natl Acad Sci. 1998;95:1.
   PubMed Web of Science ®Google Scholar
• Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022;132(4). doi:10.1172/JCI154515
   Web of Science ®Google Scholar
• Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73. doi:10.2147/JHC.S156701
   PubMed Web of Science ®Google Scholar
• Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367(1):1–11. doi:10.1016/j.canlet.2015.06.019
   PubMed Web of Science ®Google Scholar
• Fan Z, Duan J, Wang L, et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cancer Lett. 2019;450:132–143. doi:10.1016/j.canlet.2019.02.040
   PubMed Web of Science ®Google Scholar
• de Galarreta MR, Bresnahan E, Molina-Sánchez P, et al. β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116–2126. doi:10.1158/1078-0432.CCR-18-2293
   PubMed Web of Science ®Google Scholar
• Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166–2176.
   PubMed Web of Science ®Google Scholar
• Blagih J, Zani F, Chakravarty P, et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020;30(2):481–496.e6. doi:10.1016/j.celrep.2019.12.028
   PubMed Web of Science ®Google Scholar
• Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133:5.
   Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39. doi:10.1038/s41577-019-0218-4
   PubMed Web of Science ®Google Scholar
• Vu SH, Vetrivel P, Kim J, Lee M-S. Cancer Resistance to Immunotherapy: molecular Mechanisms and Tackling Strategies. Int J Mol Sci. 2022;23(18):10906. doi:10.3390/ijms231810906
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397–404.e9. doi:10.1016/j.cell.2016.08.069
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248. doi:10.1038/nrclinonc.2018.8
   PubMed Web of Science ®Google Scholar
• Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 2009;15(5):513. doi:10.3748/wjg.15.513
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1). doi:10.1186/s13073-017-0424-2
   Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Gabbia D, De Martin S. Tumor mutational burden for predicting prognosis and therapy outcome of hepatocellular carcinoma. Int J Mol Sci. 2023;24(4):3441. doi:10.3390/ijms24043441
   PubMed Web of Science ®Google Scholar
• Wong M, Kim JT, Cox B, et al. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat Oncol. 2021;8(4). doi:10.2217/hep-2020-0034
   PubMed Web of Science ®Google Scholar
• Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol. 2022;2022:112.
   Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172–1187.
   PubMedGoogle Scholar
• Wang C, Wang Z, Yao T, Zhou J, Wang Z. The immune-related role of beta-2-microglobulin in melanoma. Front Oncol. 2022;2022:12.
   Google Scholar
• Yoshihama S, Roszik J, Downs I, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016;113(21):5999–6004. doi:10.1073/pnas.1602069113
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Gotoh M, Sasaki H, Terada M, Kitajima M, Hirohashi S. Molecular cloning and initial characterization of a novel fibrinogen-related gene, HFREP-1. Biochem Biophys Res Commun. 1993;193(2):681–687. doi:10.1006/bbrc.1993.1678
   PubMed Web of Science ®Google Scholar
• Hara H, Uchida S, Yoshimura H, et al. Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration. Biochim Biophys Acta. 2000;1492(1):31–44. doi:10.1016/S0167-4781(00)00056-7
   PubMedGoogle Scholar
• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. doi:10.1038/s41422-020-0343-4
   PubMed Web of Science ®Google Scholar
• Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334–347.e12. doi:10.1016/j.cell.2018.11.010
   PubMed Web of Science ®Google Scholar
• Dutta S, Ganguly A, Chatterjee K, Spada S, Mukherjee S. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology. 2023;12(2). doi:10.3390/biology12020218
   PubMedGoogle Scholar
• Hua N, Chen A, Yang C, et al. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma. Mol Biol Rep. 2022;49(8):7911–7919. doi:10.1007/s11033-022-07624-6
   PubMed Web of Science ®Google Scholar
• Yan Q, Lin HM, Zhu K, et al. Immune checkpoint FGL1 expression of circulating tumor cells is associated with poor survival in curatively resected hepatocellular carcinoma. Front Oncol. 2022;2022:12.
   Google Scholar
• Davda J, Declerck P, Hu-Lieskovan S, et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer. 2019;7(1). doi:10.1186/s40425-019-0586-0
   PubMedGoogle Scholar
• van Brummelen EMJ, Ros W, Wolbink G, Beijnen JH, Schellens JHM. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 2016;21(10):1260–1268. doi:10.1634/theoncologist.2016-0061
   PubMed Web of Science ®Google Scholar
• Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies. 2019;8(1):21. doi:10.3390/antib8010021
   Web of Science ®Google Scholar
• Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res. 2020;26(4):787–792. doi:10.1158/1078-0432.CCR-19-2337
   PubMed Web of Science ®Google Scholar
• Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y, Zhu L. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00011
   PubMed Web of Science ®Google Scholar
• Kim C, Yang H, Kim I, et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol. 2022;8(12):1825–1829. doi:10.1001/jamaoncol.2022.4733
   PubMed Web of Science ®Google Scholar
• Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43. doi:10.1016/j.semcancer.2010.10.007
   PubMed Web of Science ®Google Scholar
• Birgani MT, Carloni V. Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy. Int J Mol Sci. 2017;18:2.
   Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27(1):16–25. doi:10.1016/j.coi.2014.01.004
   PubMedGoogle Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Sanceau J, Gougelet A. Epigenetic mechanisms of liver tumor resistance to immunotherapy. World J Hepatol. 2021;13(9):979–1002. doi:10.4254/wjh.v13.i9.979
   PubMed Web of Science ®Google Scholar
• Sheng J, Zhang J, Wang L, et al. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut. 2022;71(6):1176–1191. doi:10.1136/gutjnl-2021-324339
   PubMed Web of Science ®Google Scholar
• Lee RY, Ng CW, Rajapakse MP, Ang N, Yeong JPS, Lau MC. The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI. Front Oncol. 2023;13:1172314. doi:10.3389/fonc.2023.1172314
   PubMed Web of Science ®Google Scholar
• Feng H, Zhuo Y, Zhang X, et al. Tumor microenvironment in hepatocellular carcinoma: key players for immunotherapy. J Hepatocell Carcinoma. 2022;9:1109–1125. doi:10.2147/JHC.S381764
   PubMed Web of Science ®Google Scholar
• Workman CJ, Vignali DAA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33(4):970–979. doi:10.1002/eji.200323382
   PubMed Web of Science ®Google Scholar
• Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171:1393–1405. doi:10.1084/jem.171.5.1393
   PubMed Web of Science ®Google Scholar
• Huard B, Mastrangeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proceed Natl Acad Sci. 1997;94:5744–5749. doi:10.1073/pnas.94.11.5744
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37. doi:10.1038/ni.1679
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang A, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol. 2015;194(8):3873–3882. doi:10.4049/jimmunol.1402176
   PubMed Web of Science ®Google Scholar
• Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D. LAG3 expression in active mycobacterium tuberculosis infections. Am J Pathol. 2015;185(3):820–833. doi:10.1016/j.ajpath.2014.11.003
   PubMed Web of Science ®Google Scholar
• Butler NS, Moebius J, Pewe LL, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol. 2012;13(2):188–195. doi:10.1038/ni.2180
   Web of Science ®Google Scholar
• Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001;37(13):1709–1718. doi:10.1016/S0959-8049(01)00184-8
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108(7):2280–2289. doi:10.1182/blood-2006-04-015164
   PubMed Web of Science ®Google Scholar
• Li FJ, Zhang Y, Jin GX, Yao L, Wu DQ. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients. Immunol Lett. 2013;150(1–2):116–122. doi:10.1016/j.imlet.2012.12.004
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875–7880. doi:10.1073/pnas.1003345107
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schreiner J, Müller P, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344–1354. doi:10.1158/2326-6066.CIR-15-0097
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Kim HJ, Villasboas JC, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8(37):61425–61439.
   PubMedGoogle Scholar
• Annunziato F, Manetti R, Tomasévic I, et al. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB J. 1996;10(7):769–776. doi:10.1096/fasebj.10.7.8635694
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014. doi:10.1136/jitc-2020-001014
   PubMed Web of Science ®Google Scholar
• Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395–407. doi:10.1084/jem.20100466
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96. doi:10.1111/imr.12519
   PubMed Web of Science ®Google Scholar
• Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;2022:13.
   Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57. doi:10.1038/ni.1674
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858–17863. doi:10.1073/pnas.0903474106
   PubMed Web of Science ®Google Scholar
• Jantz-Naeem N, Böttcher-Loschinski R, Borucki K, et al. TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. Front Oncol. 2023;2023:13.
   Google Scholar
• Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT Has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338–1342. doi:10.4049/jimmunol.1003081
   PubMed Web of Science ®Google Scholar
• Levin SD, Taft DW, Brandt CS, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011;41(4):902–915. doi:10.1002/eji.201041136
   PubMed Web of Science ®Google Scholar
• Jin H, Qin S, He J, et al. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. Int J Biol Sci. 2022;18(7):2775–2794. doi:10.7150/ijbs.70691
   PubMed Web of Science ®Google Scholar
• Ge Z, Zhou G, Campos Carrascosa L, et al. TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma. CMGH. 2021;12(2):443–464. doi:10.1016/j.jcmgh.2021.03.003
   Google Scholar
• Zheng Q, Xu J, Gu X, et al. Immune checkpoint targeting TIGIT in hepatocellular carcinoma. Am J Transl Res. 2020;12(7):3212.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• Khan O, Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;571(7764):211–218. doi:10.1038/s41586-019-1325-x
   PubMed Web of Science ®Google Scholar
• Jiang W, He Y, He W, et al. Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 2021;2021:11.
   Google Scholar
• Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356.e16. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• Ma J, Zheng B, Goswami S, et al. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1). doi:10.1186/s40425-019-0814-7
   Web of Science ®Google Scholar
• Barsch M, Salié H, Schlaak AE, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol. 2022;77(2):397–409. doi:10.1016/j.jhep.2022.02.032
   PubMed Web of Science ®Google Scholar
• Colonna M. The biology of TREM receptors. Nat Rev Immunol. 2023;23:580–594. doi:10.1038/s41577-023-00837-1
   PubMedGoogle Scholar
• Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164(10):4991–4995. doi:10.4049/jimmunol.164.10.4991
   PubMed Web of Science ®Google Scholar
• Ouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410(6832):1103–1107. doi:10.1038/35074114
   PubMed Web of Science ®Google Scholar
• Gibot S, Kolopp-Sarda MN, Béné MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004;141(1):9–15. doi:10.7326/0003-4819-141-1-200407060-00009
   PubMed Web of Science ®Google Scholar
• Wang DY, Qin RY, Liu ZR, Gupta K, Chang Q. Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol. 2345;10(18):86–96.
   PubMed Web of Science ®Google Scholar
• Koussoulas V, Vassiliou S, Demonakou M, et al. Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. Eur J Gastroenterol Hepatol. 2006;18(4):375–379. doi:10.1097/00042737-200604000-00010
   PubMed Web of Science ®Google Scholar
• Zysset D, Weber B, Rihs S, et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun. 2016;7. doi:10.1038/ncomms13151
   PubMed Web of Science ®Google Scholar
• Choi ST, Kang EJ, Ha YJ, Song JS. Levels of plasma-soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) are correlated with disease activity in rheumatoid arthritis. J Rheumatol. 2012;39(5):933–938. doi:10.3899/jrheum.111218
   PubMed Web of Science ®Google Scholar
• Ho CC, Liao WY, Wang CY, et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 2008;177(7):763–770. doi:10.1164/rccm.200704-641OC
   PubMed Web of Science ®Google Scholar
• Nguyen-Lefebvre AT, Ajith A, Portik-Dobos V, et al. The innate immune receptor TREM-1 promotes liver injury and fibrosis. J Clin Invest. 2018;128(11):4870–4883. doi:10.1172/JCI98156
   PubMed Web of Science ®Google Scholar
• Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012;72(16):3977–3986. doi:10.1158/0008-5472.CAN-12-0938
   PubMed Web of Science ®Google Scholar
• Liao R, Sun TW, Yi Y, et al. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci. 2012;103(6):984–992. doi:10.1111/j.1349-7006.2012.02273.x
   PubMed Web of Science ®Google Scholar
• Muller M, Haghnejad V, Lopez A, et al. Triggering receptors expressed on myeloid cells 1: our new partner in human oncology? Front Oncol. 2022;2022:12.
   Google Scholar
• Chen J, Gingold JA, Su X. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends Mol Med. 2019;25(11):1010–1023. doi:10.1016/j.molmed.2019.06.007
   PubMed Web of Science ®Google Scholar
• Soukupova J, Malfettone A, Bertran E, et al. Epithelial–mesenchymal transition (Emt) induced by tgf-β in hepatocellular carcinoma cells reprograms lipid metabolism. Int J Mol Sci. 2021;22(11):5543. doi:10.3390/ijms22115543
   PubMed Web of Science ®Google Scholar
• Park BV, Freeman ZT, Ghasemzadeh A, et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 2016;6(12):1366–1381. doi:10.1158/2159-8290.CD-15-1347
   PubMed Web of Science ®Google Scholar
• Yin C, Evason KJ, Asahina K, Stainier DYR. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123(5):1902–1910. doi:10.1172/JCI66369
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–172. doi:10.1152/physrev.00013.2007
   PubMed Web of Science ®Google Scholar
• Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol. 1999;14(7):618–633. doi:10.1046/j.1440-1746.1999.01928.x
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218. doi:10.1172/JCI24282
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of Hepatic Fibrogenesis. Gastroenterology. 2008;134(6):1655–1669. doi:10.1053/j.gastro.2008.03.003
   PubMed Web of Science ®Google Scholar
• Yu G, Jing Y, Kou X, et al. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One. 2013;8:9.
   Web of Science ®Google Scholar
• Quiroz Reyes AG, Lozano Sepulveda SA, Martinez-Acuña N, et al. Cancer stem cell and hepatic stellate cells in hepatocellular carcinoma. Technol Cancer Res Treat. 2023;2023:22.
   Google Scholar
• Hsieh CC, Hung CH, Chiang M, Tsai YC, He JT. Hepatic stellate cells enhance liver cancer progression by inducing myeloid-derived suppressor cells through interleukin-6 signaling. Int J Mol Sci. 2019;20(20):5079. doi:10.3390/ijms20205079
   PubMed Web of Science ®Google Scholar
• Höchst B, Schildberg FA, Sauerborn P, et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol. 2013;59(3):528–535. doi:10.1016/j.jhep.2013.04.033
   PubMed Web of Science ®Google Scholar
• Yu MC, Chen CH, Liang X, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004;40(6):1312–1321. doi:10.1002/hep.20488
   PubMed Web of Science ®Google Scholar
• Dunham RM, Thapa M, Velazquez VM, et al. Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J Immunol. 2013;190(5):2009–2016. doi:10.4049/jimmunol.1201937
   PubMed Web of Science ®Google Scholar
• Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 2010;15(1):166–179. doi:10.2741/3613
   Google Scholar
• Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20(7):1723. doi:10.3390/ijms20071723
   PubMed Web of Science ®Google Scholar
• Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002–1019. doi:10.1101/gad.279737.116
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1). doi:10.1186/s12943-021-01428-1
   Web of Science ®Google Scholar
• Liu G, Sun J, Yang ZF, et al. Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. Cell Death Dis. 2021;12:3.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhao J, Li J, et al. Cancer associated fibroblast–derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis. Cell Death Dis. 2022;13(5). doi:10.1038/s41419-022-04935-1
   Web of Science ®Google Scholar
• Cheng JT, Deng YN, Yi HM, et al. Hepatic carcinoma-associated fibroblasts induce ido-producing regulatory dendritic cells through il-6-mediated stat3 activation. Oncogenesis. 2016;5(2):e198–e198. doi:10.1038/oncsis.2016.7
   PubMedGoogle Scholar
• Deng Y, Cheng J, Fu B, et al. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017;36(8):1090–1101. doi:10.1038/onc.2016.273
   PubMed Web of Science ®Google Scholar
• Harper J, Sainson RCA. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77. doi:10.1016/j.semcancer.2013.12.005
   PubMed Web of Science ®Google Scholar
• Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9(MAR). doi:10.3389/fimmu.2018.00414
   PubMedGoogle Scholar
• Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nat Commun. 2018;9(1). doi:10.1038/s41467-018-03347-0
   PubMedGoogle Scholar
• Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845–865.e7. doi:10.1016/j.ccell.2021.04.014
   PubMed Web of Science ®Google Scholar
• Liu Y, Xun Z, Ma K, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770–82.
   PubMed Web of Science ®Google Scholar
• Zhang C, Fei Y, Wang H, et al. CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy? Front Pharmacol. 2023;2023:14.
   Google Scholar
• Akkız H. Emerging role of cancer-associated fibroblasts in progression and treatment of hepatocellular carcinoma. Int J Mol Sci. 2023;24(4):3941. doi:10.3390/ijms24043941
   PubMed Web of Science ®Google Scholar
• Geva-Zatorsky N, Sefik E, Kua L, et al. Mining the human gut microbiota for immunomodulatory organisms. Cell. 2017;168(5):928–943.e11. doi:10.1016/j.cell.2017.01.022
   PubMed Web of Science ®Google Scholar
• Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine. Takeda ARjats Cls. 2020;2020:5.
   Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. doi:10.1126/science.aan3706
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084. doi:10.1126/science.aad1329
   PubMed Web of Science ®Google Scholar
• Ismail AS, Behrendt CL, Hooper LV. Reciprocal interactions between commensal bacteria and γδ Intraepithelial lymphocytes during mucosal injury. J Immunol. 2009;182(5):3047–3054. doi:10.4049/jimmunol.0802705
   PubMed Web of Science ®Google Scholar
• Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long- term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. doi:10.1371/journal.pone.0009836
   PubMed Web of Science ®Google Scholar
• Scott NA, Andrusaite A, Andersen P, et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci Transl Med. 2018;10(464). doi:10.1126/scitranslmed.aao4755
   Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–756. doi:10.1136/gutjnl-2015-310861
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771–785. doi:10.1016/j.cll.2014.08.008
   PubMed Web of Science ®Google Scholar
• Huang EY, Inoue T, Leone VA, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(5):963–972. doi:10.1097/MIB.0000000000000332
   PubMed Web of Science ®Google Scholar
• Cortellini A, Facchinetti F, Derosa L, et al. Antibiotic exposure and immune checkpoint inhibitors in patients with NSCLC: the backbone matters. J Thoracic Oncol. 2022;17(6):739–741. doi:10.1016/j.jtho.2022.03.016
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tucci M, Adamo V, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8(2):e001361. doi:10.1136/jitc-2020-001361
   PubMed Web of Science ®Google Scholar
• Cortellini A, Di Maio M, Nigro O, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4):e002421. doi:10.1136/jitc-2021-002421
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–1778. doi:10.1001/jamaoncol.2019.2785
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Li X, Mishra-Kalyani P, et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports. 2023;5(6):100747. doi:10.1016/j.jhepr.2023.100747
   PubMedGoogle Scholar
• Naqash AR, Kihn-Alarcón AJ, Stavraka C, et al. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Ann Transl Med. 2021;9(12):1034–1034. doi:10.21037/atm-20-6427
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;2021:27.
   Google Scholar
• Morita M, Nishida N, Aoki T, et al. Role of β-catenin activation in the tumor immune microenvironment and immunotherapy of hepatocellular carcinoma. Cancers. 2023;15(8):2311. doi:10.3390/cancers15082311
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou W, Yin S, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198–214. doi:10.1002/hep.30593
   PubMed Web of Science ®Google Scholar
• Han CL, Yan YC, Yan LJ, et al. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades. J Cancer Res Clin Oncol. 2022;149:1425–1441. doi:10.1007/s00432-022-04008-y
   PubMedGoogle Scholar
• Yang YQ, Wen ZY, Liu XY, et al. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol. 2023;15(2):129–150. doi:10.4254/wjh.v15.i2.129
   PubMed Web of Science ®Google Scholar
• Repáraz D, Aparicio B, Llopiz D, et al. Therapeutic vaccines against hepatocellular carcinoma in the immune checkpoint inhibitor era: time for neoantigens? Int J Mol Sci. 2022;23(4):2022. doi:10.3390/ijms23042022
   PubMed Web of Science ®Google Scholar
• Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immune-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. doi:10.1186/s13045-022-01247-x
   PubMed Web of Science ®Google Scholar
• Buonaguro L. New vaccination strategies in liver cancer. Cytokine Growth Factor Rev. 2017;36:125–129. doi:10.1016/j.cytogfr.2017.06.010
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–362.e24. doi:10.1016/j.cell.2020.08.053
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226. doi:10.1038/nature23003
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215–223. doi:10.1016/j.coi.2009.02.009
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. New England J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169
   PubMed Web of Science ®Google Scholar
• Neeson P, Shin A, Tainton KM, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8 T cells with effector and central memory-like phenotype. Gene Ther. 2010;17(9):1105–1116. doi:10.1038/gt.2010.59
   PubMed Web of Science ®Google Scholar
• Sheikh S, Migliorini D, Lang N. CAR T-based therapies in lymphoma: a review of current practice and perspectives. Biomedicines. 2022;10(8):1960. doi:10.3390/biomedicines10081960
   PubMed Web of Science ®Google Scholar
• Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10(FEB). doi:10.3389/fimmu.2019.00128
   Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052. doi:10.1172/JCI83416
   PubMed Web of Science ®Google Scholar
• Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2016;22(1):275–283. doi:10.3748/wjg.v22.i1.275
   PubMed Web of Science ®Google Scholar
• Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18(12):1591–1598. doi:10.1038/modpathol.3800436
   PubMed Web of Science ®Google Scholar
• Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418–6428. doi:10.1158/1078-0432.CCR-14-1170
   PubMed Web of Science ®Google Scholar